Clinical Trial: Breakthrough - T1DM and Chronic Kidney Disease

U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07592000) titled 'Breakthrough - T1DM and Chronic Kidney Disease' on Jan. 12.

Brief Summary: Single arm- subject treated with Tegoprubart and everolimus.

The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components:

* An investigational drug called Tegoprubart and

* Human pancreatic islet cells

Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA). Participation in this research will last about 5 years.

Assess safety, tolerability, a...